Ovensa Inc. is a Canadian, Ontario-based preclinical stage biotechnology company founded in 2012 that is commercializing a novel, best-in-class delivery platform called TRIOZAN™ focusing on advanced mucosal drug delivery of biologics and small molecules. Ovensa’s technology allows for enhanced bioavailability and targeted uptake of drugs via non-parenteral routes of administration, allowing for the effective delivery of therapeutics using the ease and convenience of oral, nasal, transdermal and ophthalmic routes as opposed to invasive injection. We bring additional advantages such as targeted delivery, drug payload internalization and crossing the blood brain barrier.

Because it crosses the blood brain barrier, TRIOZAN™ represents a significant opportunity for the treatment of CNS related diseases and cancers having high chances of brain metastasis. In cancer, brain tumours and brain metastasis express CD44 receptors. Those are targeted by TRIOZAN.

The competitive advantages of TRIOZAN are that it offers a combination of mechanisms of action. It permits to develop oral forms of delivery, a protection against the degradation in the GI environment, it has mucosae adherence, it opens the epithelial tight junctions for migration in the blood stream, it has stealth properties to hide from macrophages and it can internalize the drug in the cells while bypassing common clearance mechanisms.

The Company is targeting high-growth, billion dollar global market opportunities and has a strong business strategy with multiple paths to revenue growth including licensing its technology to strategic partners and the development of proprietary drug candidates.